iCare HOME眼压计在青光眼患者中的有效性与准确性:系统综述
本系统综述纳入18项病例系列和观察性研究,评估iCare HOME眼压计在青光眼患者中监测眼压的有效性与准确性。结果显示其与Goldmann压平眼压计(GAT)一致性良好,平均偏倚多在±2 mm Hg以内,重测信度和可重复性高(组内相关系数0.796–0.996),患者满意度高,可捕捉临床常漏诊的日间眼压波动。
要点
- iCare HOME与GAT一致性良好,平均偏倚多在±2 mm Hg以内。
- 重测信度和可重复性高,组内相关系数范围为0.796–0.996。
- 多数患者经适当指导后可获得可靠读数,远程培训效果良好。
核心结论
- iCare HOME眼压计是青光眼居家眼压监测中可靠且可行的工具,在适当条件下性能与GAT相当。
- 将其整合到远程眼科中可能改善疾病管理、减少门诊就诊并赋能患者,尤其适合需要密切监测或存在眼压波动的患者。
研究设计与样本
- 遵循PRISMA 2020和AMSTAR 2指南,系统检索PubMed和Cochrane Library数据库2017年1月至2025年2月的文献。
- 共纳入18项符合标准的研究,包括病例系列和观察性研究,提取并分析眼压测量准确性、重测信度、可重复性及患者相关因素的数据。
主要发现
- iCare HOME眼压计与GAT一致性良好,平均偏倚多在±2 mm Hg以内。
- 影响因素包括中央角膜厚度、角膜生物力学、对准和用户培训。
- 重测信度和可重复性高,组内相关系数范围为0.796–0.996。
- 多数患者经适当指导后可获得可靠读数;初始使用存在挑战,尤其在对准方面,但熟悉后操作表现改善;远程培训显示出良好效果。
- 患者满意度高,但部分患者指出频繁测量的负担;居家监测具有节省时间的优势,并可捕捉临床环境中常被漏诊的日间眼压波动。
关键数值与推荐
- 与GAT的平均偏倚多在±2 mm Hg以内。
- 组内相关系数范围为0.796–0.996。
- 成本差异仍不明确。
临床怎么用
- 原文结论认为iCare HOME眼压计是青光眼居家眼压监测中可靠且可行的工具,在适当条件下性能与GAT相当。
- 原文结论提出将其整合到远程眼科中可能改善疾病管理、减少门诊就诊并赋能患者,尤其适合需要密切监测或存在眼压波动的患者。
局限性
- 成本差异仍不明确。
- 部分患者指出频繁测量的负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the effectiveness and accuracy of the iCare HOME tonometer for intraocular pressure (IOP) monitoring in glaucoma patients, comparing its performance to the clinical gold standard, Goldmann applanation tonometry (GAT). METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 and Assessing the Methodological Quality of Systematic Reviews (AMSTAR) 2 guidelines, a systematic search of the PubMed and Cochrane Library databases from January 2017 to February 2025 was conducted. A total of 18 studies, including case series and observational studies, met inclusion criteria. Data on IOP measurement accuracy, repeatability, reproducibility, and patient-related factors were extracted and analyzed. RESULTS: The iCare HOME tonometer demonstrated good agreement with GAT, with mean biases generally within ±2 mm Hg. Influencing factors included central corneal thickness, corneal biomechanics, alignment, and user training. Repeatability and reproducibility were high, with intraclass correlation coefficients ranging from 0.796 to 0.996. Most patients were able to obtain reliable readings after appropriate instruction. Although initial use posed challenges, especially with alignment, familiarity improved performance. Remote training showed promising outcomes. Patient satisfaction was high, although some patients noted the burden of frequent measurements. Although cost differences remain unclear, home monitoring offered time-saving advantages and captured diurnal IOP fluctuations, which were often missed in clinical settings. CONCLUSIONS: The iCare HOME tonometer is a reliable and feasible tool for at-home IOP monitoring in glaucoma care, offering performance comparable to that of GAT under proper conditions. Its integration into teleophthalmology may enhance disease management, reduce clinic visits, and empower patients, especially those who would benefit from close monitoring or who are experiencing IOP fluctuations.
引用
- Pons-Talaya C, Pons-Talaya A, Widmer J, et al. Effectiveness and Accuracy of iCare HOME Tonometer in Glaucoma Patients: A Systematic Review. Am J Ophthalmol. 2025. PMID: 41110676. doi:10.1016/j.ajo.2025.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。